CM
COGT icon

Caption Management’s Cogent Biosciences COGT Stock Holding History

Caption Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94M Hold
50,000
– – 0.01% 915
2026
Q1 		$1.92M Buy
+50,000
New +$1.85M 0.01% 832
2025
Q4 		– Sell
-135,000
Closed -$1.94M – 1640
2025
Q3 		$1.94M Sell
135,000
-335,300
-71% -$3.97M 0.02% 856
2025
Q2 		$3.38M Buy
+470,300
New +$2.61M 0.04% 532
2025
Q1 		– Sell
-202,500
Closed -$1.58M – 1603
2024
Q4 		$1.58M Buy
+202,500
New +$2.02M 0.01% 783
2024
Q2 		– Sell
-39,800
Closed -$267K – 1210
2024
Q1 		$267K Buy
+39,800
New +$246K ﹤0.01% 966
2022
Q3 		– Sell
-104,600
Closed -$943K – 1551
2022
Q2 		$943K Buy
+104,600
New +$714K 0.01% 897

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Caption Management's COGT Position: Q2 2026 in Review

Caption Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 20,000 shares — an estimated $700K sold.

Caption Management first reported a position in COGT in Q2 2022 and held it in 6 quarters. The position peaked at $3.14M in Q2 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Caption Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 20,000 Cogent Biosciences shares in Q2 2026, an estimated $700K.
  • Caption Management first reported a position in Cogent Biosciences in Q2 2022 and held it in 6 quarters.
  • Caption Management's Cogent Biosciences position peaked at $3.14M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.